IL-DISCOVER-FINANCIAL
7.6.2019 16:12:07 CEST | Business Wire | Press release
Borica AD, owner of Bulgaria’s national payment scheme Bcard and Discover Financial Services, a leading direct bank and payments services company announced that they have signed a strategic agreement that will allow acceptance of Bcard’s Global Cards outside of Bulgaria on the Discover Global Network.
To help provide safer international transactions, Bcard and Discover will collaborate on the integration of Discover’s EMV® contact, contactless and mobile solutions, D-PAS for international usage. Bcard will also provide their member banks with a solution to support the acceptance of Bcard’s Global Cards outside of Bulgaria on the Discover Global Network.
“Discover has become a nimble and flexible partner to organizations around the world by providing them the tools and resources to grow and increase acceptance,” said Joe Hurley, senior vice president and head of global business development at Discover. “This agreement with Bcard complements Discover’s strategy of creating worldwide alliances that provide consumers with more choice when it comes to how and where they pay.”
“The investment in innovation and the development of solutions as extending acceptance outside the territory of Bulgaria for our customers has always been among Bcard’s priorities,” said Mrs. Stoilka Arsova, director of Bulgarian national scheme Bcard. “Bulgaria has accumulated knowledge, experience and technology and achieved world-class standards in terms of financial technology and security and this strategic alliance with Discover reinforces Bcard's continuous efforts to diversify its card-payment services for our banks and promote Bulgaria's card-payment market development. Based on this strategic alliance, Bcard will provide their member banks with an effective competitive domestic platform, range of products and the opportunity to use innovative payment products.”
Discover Global Network has more than 44 million merchant acceptance locations and 2 million ATM and cash access locations across more than 190 countries and territories. Discover Global Network includes Discover, Diners Club International, PULSE and affiliated networks. It also includes network relationships with partners around the globe in Brazil, China, India, Japan, the Middle East, Nigeria, Puerto Rico, Serbia, South Korea, Vietnam, Taiwan, Mexico and throughout Europe.
About Bcard
Bcard National Card Scheme of Borica AD has been in operation since 2016 and functions separately and independently from the card payment processor of Borica.
All payment service providers in Bulgaria are members of the Bcard scheme. Bcard, as a Bulgarian national payment card, is accepted at all possible locations (ATM/POS) in Bulgaria. The main mission of the scheme is migration of cash and paper to digital channels through development of new electronic services in the public and private sectors in Bulgaria. Positioning the wide range of scheme products through new local business and price models is expected to have a positive impact on the economy of the country and to change radically the payment methods in Bulgaria.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190607005310/en/
Contact:
Media Contacts: Elena Tosheva Head of Marketing and Communications Bcard M: + 359 884 292 192 E: ETosheva@borica.bg
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom